Effect of aging and dopaminomimetic therapy on mitochondrial respiratory function in Parkinson's disease
Identifieur interne : 009311 ( Main/Merge ); précédent : 009310; suivant : 009312Effect of aging and dopaminomimetic therapy on mitochondrial respiratory function in Parkinson's disease
Auteurs : Daniele Bravi [États-Unis] ; Jeffrey J. Anderson [États-Unis] ; Fiorenzo Dagani [Italie] ; Thomas L. Davis [États-Unis] ; Rosaria Ferrari [Italie] ; Marge Gillespie [États-Unis] ; Chase [États-Unis]Source :
- Movement Disorders [ 0885-3185 ] ; 1992.
Descripteurs français
- Wicri :
- topic : Glucose.
English descriptors
- KwdEn :
- Age Factors, Blood Glucose (metabolism), Blood Platelets (drug effects), Blood Platelets (physiology), Carbidopa (administration & dosage), Drug Therapy, Combination, Energy Metabolism (drug effects), Energy Metabolism (physiology), Female, Glucose, Humans, Lactate, Lactates (blood), Lactic Acid, Levodopa (administration & dosage), Lisuride (administration & dosage), Male, Middle Aged, Mitochondria, Mitochondria (drug effects), Mitochondria (physiology), Oxygen Consumption (drug effects), Oxygen Consumption (physiology), Parkinson Disease (drug therapy), Parkinson Disease (physiopathology), Platelets, Receptors, Dopamine (drug effects), Receptors, Dopamine (physiology), Respiration, Selegiline (administration & dosage).
- MESH :
- chemical , administration & dosage : Carbidopa, Levodopa, Lisuride, Selegiline.
- chemical , blood : Lactates.
- chemical , drug effects : Receptors, Dopamine.
- chemical , metabolism : Blood Glucose.
- drug effects : Blood Platelets, Energy Metabolism, Mitochondria, Oxygen Consumption.
- drug therapy : Parkinson Disease.
- physiology : Blood Platelets, Energy Metabolism, Mitochondria, Oxygen Consumption, Receptors, Dopamine.
- physiopathology : Parkinson Disease.
- Age Factors, Drug Therapy, Combination, Female, Humans, Lactic Acid, Male, Middle Aged.
Abstract
Oxygen consumption and enzyme activity were evaluted in platelet mitochondria from 17 patients with Parkinson's disease. In comparison with age‐matched controls, no consistent abnormality could be discerned in complex I, complex II‐III, or complex IV oxygen consumption, or in the enzyme activity of these respiratory chain complexes. Neither chronic therapy with levodopa/carbidopa alone nor in combination with deprenyl significantly affected any measure of mitochondrial respiratory function. There was no discernible relationship between patient age or disease severity and any parameter of mitochondrial respiration. Moreover, blood lactate levels following glucose loading were not different in patients and controls. These results fail to support the occurrence of a generalized defect in any mitochondrial respiratory function in Parkinson's disease.
Url:
DOI: 10.1002/mds.870070307
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 003322
- to stream Istex, to step Curation: 003322
- to stream Istex, to step Checkpoint: 004221
- to stream PubMed, to step Corpus: 004D33
- to stream PubMed, to step Curation: 004D33
- to stream PubMed, to step Checkpoint: 004D57
- to stream Ncbi, to step Merge: 001457
- to stream Ncbi, to step Curation: 001457
- to stream Ncbi, to step Checkpoint: 001457
Links to Exploration step
ISTEX:CC5EF4266868D9B9A52A82A774207936C3DFFF8ALe document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Effect of aging and dopaminomimetic therapy on mitochondrial respiratory function in Parkinson's disease</title><author><name sortKey="Bravi, Daniele" sort="Bravi, Daniele" uniqKey="Bravi D" first="Daniele" last="Bravi">Daniele Bravi</name></author><author><name sortKey="Anderson, Jeffrey J" sort="Anderson, Jeffrey J" uniqKey="Anderson J" first="Jeffrey J." last="Anderson">Jeffrey J. Anderson</name></author><author><name sortKey="Dagani, Fiorenzo" sort="Dagani, Fiorenzo" uniqKey="Dagani F" first="Fiorenzo" last="Dagani">Fiorenzo Dagani</name></author><author><name sortKey="Davis, Thomas L" sort="Davis, Thomas L" uniqKey="Davis T" first="Thomas L." last="Davis">Thomas L. Davis</name></author><author><name sortKey="Ferrari, Rosaria" sort="Ferrari, Rosaria" uniqKey="Ferrari R" first="Rosaria" last="Ferrari">Rosaria Ferrari</name></author><author><name sortKey="Gillespie, Marge" sort="Gillespie, Marge" uniqKey="Gillespie M" first="Marge" last="Gillespie">Marge Gillespie</name></author><author><name sortKey="Chase" sort="Chase" uniqKey="Chase" last="Chase">Chase</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:CC5EF4266868D9B9A52A82A774207936C3DFFF8A</idno><date when="1992" year="1992">1992</date><idno type="doi">10.1002/mds.870070307</idno><idno type="url">https://api.istex.fr/document/CC5EF4266868D9B9A52A82A774207936C3DFFF8A/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">003322</idno><idno type="wicri:Area/Istex/Curation">003322</idno><idno type="wicri:Area/Istex/Checkpoint">004221</idno><idno type="wicri:doubleKey">0885-3185:1992:Bravi D:effect:of:aging</idno><idno type="wicri:source">PubMed</idno><idno type="RBID">pubmed:1620140</idno><idno type="wicri:Area/PubMed/Corpus">004D33</idno><idno type="wicri:Area/PubMed/Curation">004D33</idno><idno type="wicri:Area/PubMed/Checkpoint">004D57</idno><idno type="wicri:Area/Ncbi/Merge">001457</idno><idno type="wicri:Area/Ncbi/Curation">001457</idno><idno type="wicri:Area/Ncbi/Checkpoint">001457</idno><idno type="wicri:doubleKey">0885-3185:1992:Bravi D:effect:of:aging</idno><idno type="wicri:Area/Main/Merge">009311</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Effect of aging and dopaminomimetic therapy on mitochondrial respiratory function in Parkinson's disease</title><author><name sortKey="Bravi, Daniele" sort="Bravi, Daniele" uniqKey="Bravi D" first="Daniele" last="Bravi">Daniele Bravi</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Experimental Therapeutics Branch, NINDS, NIH, Bethesda, Maryland</wicri:regionArea><placeName><region type="state">Maryland</region></placeName></affiliation></author><author><name sortKey="Anderson, Jeffrey J" sort="Anderson, Jeffrey J" uniqKey="Anderson J" first="Jeffrey J." last="Anderson">Jeffrey J. Anderson</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Experimental Therapeutics Branch, NINDS, NIH, Bethesda, Maryland</wicri:regionArea><placeName><region type="state">Maryland</region></placeName></affiliation></author><author><name sortKey="Dagani, Fiorenzo" sort="Dagani, Fiorenzo" uniqKey="Dagani F" first="Fiorenzo" last="Dagani">Fiorenzo Dagani</name><affiliation wicri:level="1"><country xml:lang="fr">Italie</country><wicri:regionArea>Instiute of Pharmacology, University of Pavia, Pavia</wicri:regionArea><wicri:noRegion>Pavia</wicri:noRegion></affiliation></author><author><name sortKey="Davis, Thomas L" sort="Davis, Thomas L" uniqKey="Davis T" first="Thomas L." last="Davis">Thomas L. Davis</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Experimental Therapeutics Branch, NINDS, NIH, Bethesda, Maryland</wicri:regionArea><placeName><region type="state">Maryland</region></placeName></affiliation></author><author><name sortKey="Ferrari, Rosaria" sort="Ferrari, Rosaria" uniqKey="Ferrari R" first="Rosaria" last="Ferrari">Rosaria Ferrari</name><affiliation wicri:level="1"><country xml:lang="fr">Italie</country><wicri:regionArea>Instiute of Pharmacology, University of Pavia, Pavia</wicri:regionArea><wicri:noRegion>Pavia</wicri:noRegion></affiliation></author><author><name sortKey="Gillespie, Marge" sort="Gillespie, Marge" uniqKey="Gillespie M" first="Marge" last="Gillespie">Marge Gillespie</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Experimental Therapeutics Branch, NINDS, NIH, Bethesda, Maryland</wicri:regionArea><placeName><region type="state">Maryland</region></placeName></affiliation></author><author><name sortKey="Chase" sort="Chase" uniqKey="Chase" last="Chase">Chase</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Experimental Therapeutics Branch, NINDS, NIH, Bethesda, Maryland</wicri:regionArea><placeName><region type="state">Maryland</region></placeName></affiliation></author></analytic><monogr></monogr><series><title level="j">Movement Disorders</title><title level="j" type="sub">Official Journal of the Movement Disorder Society</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="ISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="1992">1992</date><biblScope unit="vol">7</biblScope><biblScope unit="issue">3</biblScope><biblScope unit="page" from="228">228</biblScope><biblScope unit="page" to="231">231</biblScope></imprint><idno type="ISSN">0885-3185</idno></series><idno type="istex">CC5EF4266868D9B9A52A82A774207936C3DFFF8A</idno><idno type="DOI">10.1002/mds.870070307</idno><idno type="ArticleID">MDS870070307</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Age Factors</term><term>Blood Glucose (metabolism)</term><term>Blood Platelets (drug effects)</term><term>Blood Platelets (physiology)</term><term>Carbidopa (administration & dosage)</term><term>Drug Therapy, Combination</term><term>Energy Metabolism (drug effects)</term><term>Energy Metabolism (physiology)</term><term>Female</term><term>Glucose</term><term>Humans</term><term>Lactate</term><term>Lactates (blood)</term><term>Lactic Acid</term><term>Levodopa (administration & dosage)</term><term>Lisuride (administration & dosage)</term><term>Male</term><term>Middle Aged</term><term>Mitochondria</term><term>Mitochondria (drug effects)</term><term>Mitochondria (physiology)</term><term>Oxygen Consumption (drug effects)</term><term>Oxygen Consumption (physiology)</term><term>Parkinson Disease (drug therapy)</term><term>Parkinson Disease (physiopathology)</term><term>Platelets</term><term>Receptors, Dopamine (drug effects)</term><term>Receptors, Dopamine (physiology)</term><term>Respiration</term><term>Selegiline (administration & dosage)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Carbidopa</term><term>Levodopa</term><term>Lisuride</term><term>Selegiline</term></keywords><keywords scheme="MESH" type="chemical" qualifier="blood" xml:lang="en"><term>Lactates</term></keywords><keywords scheme="MESH" type="chemical" qualifier="drug effects" xml:lang="en"><term>Receptors, Dopamine</term></keywords><keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en"><term>Blood Glucose</term></keywords><keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Glucose</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Blood Platelets</term><term>Energy Metabolism</term><term>Mitochondria</term><term>Oxygen Consumption</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="physiology" xml:lang="en"><term>Blood Platelets</term><term>Energy Metabolism</term><term>Mitochondria</term><term>Oxygen Consumption</term><term>Receptors, Dopamine</term></keywords><keywords scheme="MESH" qualifier="physiopathology" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Age Factors</term><term>Drug Therapy, Combination</term><term>Female</term><term>Humans</term><term>Lactic Acid</term><term>Male</term><term>Middle Aged</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Oxygen consumption and enzyme activity were evaluted in platelet mitochondria from 17 patients with Parkinson's disease. In comparison with age‐matched controls, no consistent abnormality could be discerned in complex I, complex II‐III, or complex IV oxygen consumption, or in the enzyme activity of these respiratory chain complexes. Neither chronic therapy with levodopa/carbidopa alone nor in combination with deprenyl significantly affected any measure of mitochondrial respiratory function. There was no discernible relationship between patient age or disease severity and any parameter of mitochondrial respiration. Moreover, blood lactate levels following glucose loading were not different in patients and controls. These results fail to support the occurrence of a generalized defect in any mitochondrial respiratory function in Parkinson's disease.</div></front></TEI><double doi="10.1002/mds.870070307"><ISTEX><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Effect of aging and dopaminomimetic therapy on mitochondrial respiratory function in Parkinson's disease</title><author><name sortKey="Bravi, Daniele" sort="Bravi, Daniele" uniqKey="Bravi D" first="Daniele" last="Bravi">Daniele Bravi</name></author><author><name sortKey="Anderson, Jeffrey J" sort="Anderson, Jeffrey J" uniqKey="Anderson J" first="Jeffrey J." last="Anderson">Jeffrey J. Anderson</name></author><author><name sortKey="Dagani, Fiorenzo" sort="Dagani, Fiorenzo" uniqKey="Dagani F" first="Fiorenzo" last="Dagani">Fiorenzo Dagani</name></author><author><name sortKey="Davis, Thomas L" sort="Davis, Thomas L" uniqKey="Davis T" first="Thomas L." last="Davis">Thomas L. Davis</name></author><author><name sortKey="Ferrari, Rosaria" sort="Ferrari, Rosaria" uniqKey="Ferrari R" first="Rosaria" last="Ferrari">Rosaria Ferrari</name></author><author><name sortKey="Gillespie, Marge" sort="Gillespie, Marge" uniqKey="Gillespie M" first="Marge" last="Gillespie">Marge Gillespie</name></author><author><name sortKey="Chase" sort="Chase" uniqKey="Chase" last="Chase">Chase</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:CC5EF4266868D9B9A52A82A774207936C3DFFF8A</idno><date when="1992" year="1992">1992</date><idno type="doi">10.1002/mds.870070307</idno><idno type="url">https://api.istex.fr/document/CC5EF4266868D9B9A52A82A774207936C3DFFF8A/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">003322</idno><idno type="wicri:Area/Istex/Curation">003322</idno><idno type="wicri:Area/Istex/Checkpoint">004221</idno><idno type="wicri:doubleKey">0885-3185:1992:Bravi D:effect:of:aging</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Effect of aging and dopaminomimetic therapy on mitochondrial respiratory function in Parkinson's disease</title><author><name sortKey="Bravi, Daniele" sort="Bravi, Daniele" uniqKey="Bravi D" first="Daniele" last="Bravi">Daniele Bravi</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Experimental Therapeutics Branch, NINDS, NIH, Bethesda, Maryland</wicri:regionArea><placeName><region type="state">Maryland</region></placeName></affiliation></author><author><name sortKey="Anderson, Jeffrey J" sort="Anderson, Jeffrey J" uniqKey="Anderson J" first="Jeffrey J." last="Anderson">Jeffrey J. Anderson</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Experimental Therapeutics Branch, NINDS, NIH, Bethesda, Maryland</wicri:regionArea><placeName><region type="state">Maryland</region></placeName></affiliation></author><author><name sortKey="Dagani, Fiorenzo" sort="Dagani, Fiorenzo" uniqKey="Dagani F" first="Fiorenzo" last="Dagani">Fiorenzo Dagani</name><affiliation wicri:level="1"><country xml:lang="fr">Italie</country><wicri:regionArea>Instiute of Pharmacology, University of Pavia, Pavia</wicri:regionArea><wicri:noRegion>Pavia</wicri:noRegion></affiliation></author><author><name sortKey="Davis, Thomas L" sort="Davis, Thomas L" uniqKey="Davis T" first="Thomas L." last="Davis">Thomas L. Davis</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Experimental Therapeutics Branch, NINDS, NIH, Bethesda, Maryland</wicri:regionArea><placeName><region type="state">Maryland</region></placeName></affiliation></author><author><name sortKey="Ferrari, Rosaria" sort="Ferrari, Rosaria" uniqKey="Ferrari R" first="Rosaria" last="Ferrari">Rosaria Ferrari</name><affiliation wicri:level="1"><country xml:lang="fr">Italie</country><wicri:regionArea>Instiute of Pharmacology, University of Pavia, Pavia</wicri:regionArea><wicri:noRegion>Pavia</wicri:noRegion></affiliation></author><author><name sortKey="Gillespie, Marge" sort="Gillespie, Marge" uniqKey="Gillespie M" first="Marge" last="Gillespie">Marge Gillespie</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Experimental Therapeutics Branch, NINDS, NIH, Bethesda, Maryland</wicri:regionArea><placeName><region type="state">Maryland</region></placeName></affiliation></author><author><name sortKey="Chase" sort="Chase" uniqKey="Chase" last="Chase">Chase</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Experimental Therapeutics Branch, NINDS, NIH, Bethesda, Maryland</wicri:regionArea><placeName><region type="state">Maryland</region></placeName></affiliation></author></analytic><monogr></monogr><series><title level="j">Movement Disorders</title><title level="j" type="sub">Official Journal of the Movement Disorder Society</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="ISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="1992">1992</date><biblScope unit="vol">7</biblScope><biblScope unit="issue">3</biblScope><biblScope unit="page" from="228">228</biblScope><biblScope unit="page" to="231">231</biblScope></imprint><idno type="ISSN">0885-3185</idno></series><idno type="istex">CC5EF4266868D9B9A52A82A774207936C3DFFF8A</idno><idno type="DOI">10.1002/mds.870070307</idno><idno type="ArticleID">MDS870070307</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Glucose</term><term>Lactate</term><term>Mitochondria</term><term>Platelets</term><term>Respiration</term></keywords><keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Glucose</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Oxygen consumption and enzyme activity were evaluted in platelet mitochondria from 17 patients with Parkinson's disease. In comparison with age‐matched controls, no consistent abnormality could be discerned in complex I, complex II‐III, or complex IV oxygen consumption, or in the enzyme activity of these respiratory chain complexes. Neither chronic therapy with levodopa/carbidopa alone nor in combination with deprenyl significantly affected any measure of mitochondrial respiratory function. There was no discernible relationship between patient age or disease severity and any parameter of mitochondrial respiration. Moreover, blood lactate levels following glucose loading were not different in patients and controls. These results fail to support the occurrence of a generalized defect in any mitochondrial respiratory function in Parkinson's disease.</div></front></TEI></ISTEX><PubMed><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Effect of aging and dopaminomimetic therapy on mitochondrial respiratory function in Parkinson's disease.</title><author><name sortKey="Bravi, D" sort="Bravi, D" uniqKey="Bravi D" first="D" last="Bravi">D. Bravi</name><affiliation wicri:level="2"><nlm:affiliation>Experimental Therapeutics Branch, NINDS, NIH, Bethesda, Maryland 20892.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Maryland</region></placeName><wicri:cityArea>Experimental Therapeutics Branch, NINDS, NIH, Bethesda</wicri:cityArea></affiliation></author><author><name sortKey="Anderson, J J" sort="Anderson, J J" uniqKey="Anderson J" first="J J" last="Anderson">J J Anderson</name></author><author><name sortKey="Dagani, F" sort="Dagani, F" uniqKey="Dagani F" first="F" last="Dagani">F. Dagani</name></author><author><name sortKey="Davis, T L" sort="Davis, T L" uniqKey="Davis T" first="T L" last="Davis">T L Davis</name></author><author><name sortKey="Ferrari, R" sort="Ferrari, R" uniqKey="Ferrari R" first="R" last="Ferrari">R. Ferrari</name></author><author><name sortKey="Gillespie, M" sort="Gillespie, M" uniqKey="Gillespie M" first="M" last="Gillespie">M. Gillespie</name></author><author><name sortKey="Chase, T N" sort="Chase, T N" uniqKey="Chase T" first="T N" last="Chase">T N Chase</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="1992">1992</date><idno type="RBID">pubmed:1620140</idno><idno type="pmid">1620140</idno><idno type="doi">10.1002/mds.870070307</idno><idno type="wicri:Area/PubMed/Corpus">004D33</idno><idno type="wicri:Area/PubMed/Curation">004D33</idno><idno type="wicri:Area/PubMed/Checkpoint">004D57</idno><idno type="wicri:Area/Ncbi/Merge">001457</idno><idno type="wicri:Area/Ncbi/Curation">001457</idno><idno type="wicri:Area/Ncbi/Checkpoint">001457</idno><idno type="wicri:doubleKey">0885-3185:1992:Bravi D:effect:of:aging</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Effect of aging and dopaminomimetic therapy on mitochondrial respiratory function in Parkinson's disease.</title><author><name sortKey="Bravi, D" sort="Bravi, D" uniqKey="Bravi D" first="D" last="Bravi">D. Bravi</name><affiliation wicri:level="2"><nlm:affiliation>Experimental Therapeutics Branch, NINDS, NIH, Bethesda, Maryland 20892.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Maryland</region></placeName><wicri:cityArea>Experimental Therapeutics Branch, NINDS, NIH, Bethesda</wicri:cityArea></affiliation></author><author><name sortKey="Anderson, J J" sort="Anderson, J J" uniqKey="Anderson J" first="J J" last="Anderson">J J Anderson</name></author><author><name sortKey="Dagani, F" sort="Dagani, F" uniqKey="Dagani F" first="F" last="Dagani">F. Dagani</name></author><author><name sortKey="Davis, T L" sort="Davis, T L" uniqKey="Davis T" first="T L" last="Davis">T L Davis</name></author><author><name sortKey="Ferrari, R" sort="Ferrari, R" uniqKey="Ferrari R" first="R" last="Ferrari">R. Ferrari</name></author><author><name sortKey="Gillespie, M" sort="Gillespie, M" uniqKey="Gillespie M" first="M" last="Gillespie">M. Gillespie</name></author><author><name sortKey="Chase, T N" sort="Chase, T N" uniqKey="Chase T" first="T N" last="Chase">T N Chase</name></author></analytic><series><title level="j">Movement disorders : official journal of the Movement Disorder Society</title><idno type="ISSN">0885-3185</idno><imprint><date when="1992" type="published">1992</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Age Factors</term><term>Blood Glucose (metabolism)</term><term>Blood Platelets (drug effects)</term><term>Blood Platelets (physiology)</term><term>Carbidopa (administration & dosage)</term><term>Drug Therapy, Combination</term><term>Energy Metabolism (drug effects)</term><term>Energy Metabolism (physiology)</term><term>Female</term><term>Humans</term><term>Lactates (blood)</term><term>Lactic Acid</term><term>Levodopa (administration & dosage)</term><term>Lisuride (administration & dosage)</term><term>Male</term><term>Middle Aged</term><term>Mitochondria (drug effects)</term><term>Mitochondria (physiology)</term><term>Oxygen Consumption (drug effects)</term><term>Oxygen Consumption (physiology)</term><term>Parkinson Disease (drug therapy)</term><term>Parkinson Disease (physiopathology)</term><term>Receptors, Dopamine (drug effects)</term><term>Receptors, Dopamine (physiology)</term><term>Selegiline (administration & dosage)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Carbidopa</term><term>Levodopa</term><term>Lisuride</term><term>Selegiline</term></keywords><keywords scheme="MESH" type="chemical" qualifier="blood" xml:lang="en"><term>Lactates</term></keywords><keywords scheme="MESH" type="chemical" qualifier="drug effects" xml:lang="en"><term>Receptors, Dopamine</term></keywords><keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en"><term>Blood Glucose</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Blood Platelets</term><term>Energy Metabolism</term><term>Mitochondria</term><term>Oxygen Consumption</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="physiology" xml:lang="en"><term>Blood Platelets</term><term>Energy Metabolism</term><term>Mitochondria</term><term>Oxygen Consumption</term><term>Receptors, Dopamine</term></keywords><keywords scheme="MESH" qualifier="physiopathology" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Age Factors</term><term>Drug Therapy, Combination</term><term>Female</term><term>Humans</term><term>Lactic Acid</term><term>Male</term><term>Middle Aged</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Oxygen consumption and enzyme activity were evaluated in platelet mitochondria from 17 patients with Parkinson's disease. In comparison with age-matched controls, no consistent abnormality could be discerned in complex I, complex II-III, or complex IV oxygen consumption, or in the enzyme activity of these respiratory chain complexes. Neither chronic therapy with levodopa/carbidopa alone nor in combination with deprenyl significantly affected any measure of mitochondrial respiratory function. There was no discernible relationship between patient age or disease severity and any parameter of mitochondrial respiration. Moreover, blood lactate levels following glucose loading were not different in patients and controls. These results fail to support the occurrence of a generalized defect in any mitochondrial respiratory function in Parkinson's disease.</div></front></TEI></PubMed></double></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Main/Merge
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 009311 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Merge/biblio.hfd -nk 009311 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= Main
|étape= Merge
|type= RBID
|clé= ISTEX:CC5EF4266868D9B9A52A82A774207936C3DFFF8A
|texte= Effect of aging and dopaminomimetic therapy on mitochondrial respiratory function in Parkinson's disease
}}
| This area was generated with Dilib version V0.6.23. |  |